In terms of clinical mechanisms, reducing inflammatory markers such as CRP and TNF-α can significantly alleviate systemic inflammation, thereby decreasing the risk of complications like vascular dysfunction and insulin resistance (84, 85). This evidence concerns the gene TNF and Insulin resistance.